Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

FLT3 mutation + IDH1 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

FLT3-ITD mutation (90)

IDH1 mutation (79)

FLT3 mutation (67)

FLT3-TKD mutation (13)

FLT3 D835Y (12)

FLT3 F691L (11)

FLT3-ITD mutation + FLT3-TKD mutation (5)

DNMT3A mutation + FLT3-ITD mutation (4)

FLT3 mutation + NPM1 mutation (4)

FLT3 N676D + FLT3 Y842C (3)

FLT3 mutation + DNMT3A mutation (3)

FLT3 mutation + NRAS mutation (3)

FLT3 wild-type (3)

FLT3-ITD mutation + FLT3 D835 (3)

FLT3-ITD mutation + MLL rearrangement (3)

FLT3-ITD mutation + NPM1 mutation (3)

FLT3‐ITD + NPM1 mutation (3)

FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation (3)

IDH wild-type (3)

FLT3 mutation + MLL mutation (2)

FLT3-ITD mutation + FLT3 D835Y (2)

FLT3-ITD mutation + FLT3 F691L (2)

FLT3-ITD mutation + IDH1 mutation (2)

FLT3-ITD mutation + IDH2 mutation (2)

FLT3-ITD mutation + WT1 mutation (2)

IDH1 wild-type + BRAF mutation (2)

IDH1 wild-type + NF1 mutation (2)

CEBPZ rearrangement + FLT3-TKD mutation (1)

FLT3 E588_Y589INSKYFYVDFRE (1)

FLT3 F691L + FLT3 D835F (1)

FLT3 F691L + FLT3 D835H (1)

FLT3 F691L + FLT3 D835V (1)

FLT3 F691L + FLT3 D835Y (1)

FLT3 F691L + FLT3 D839G (1)

FLT3 F691L + FLT3 Y842C (1)

FLT3 NPOS + FLT3 D835N (1)

FLT3 V592A + FLT3 D835N (1)

FLT3 V592_D593INSDFREY (1)

FLT3 Y591_V592INSVDFREYE (1)

FLT3 mutation + NRAS mutation + PTPN11 mutation (1)

FLT3 mutation + PTPN11 mutation (1)

FLT3 positive (1)

FLT3-ITD F692L + NPM1 mutation (1)

FLT3-ITD mutation + ASXL1 mutation (1)

FLT3-ITD mutation + ASXL1 mutation + NRAS mutation (1)

FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation (1)

FLT3-ITD mutation + DNMT3A mutation + NRAS mutation (1)

FLT3-ITD mutation + FLT3 D835Y + FLT3 F691L (1)

FLT3-ITD mutation + NRAS mutation + GATA2 mutation (1)

FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

FLT3‐ITD + DNMT3A mutation (1)

FLT3‐ITD + WT1 mutation (1)

MLL rearrangement + FLT3 mutation (1)

NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation (1)

NPM1 mutation + FLT3-TKD mutation (1)

NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

DNMT3A mutation + IDH mutation (1)

EGFR L858R + IDH1 R132C (1)

EGFR mutation + IDH1 mutation (1)

EGFR mutation+ IDH1 R132H (1)

IDH1 R132C + EGFR L861Q (1)

IDH1 R132C + IDH1 S280F (1)

IDH1 R132C + PIK3CA E545K + IDH2 R172K (1)

IDH1 R132H + PTEN C78T (1)

IDH1 mutation + TP53 mutation (1)

IDH1 rs1437410 (1)

FLT3 F691L + FLT3 Y842H (0)

FLT3-ITD F692L (0)

IDH mutation + BRAF V600E (0)

IDH mutation + Chr del(1p) + Chr del(19q) (0)

IDH mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (0)

IDH mutation + Chr del(1p) + Chr del(19q) + NTRK fusion (0)

IDH mutation + NTRK fusion (0)

FLT3-ITD mutation (90)

IDH1 mutation (79)

FLT3 mutation (67)

FLT3-TKD mutation (13)

FLT3 D835Y (12)

FLT3 F691L (11)

FLT3-ITD mutation + FLT3-TKD mutation (5)

DNMT3A mutation + FLT3-ITD mutation (4)

FLT3 mutation + NPM1 mutation (4)

FLT3 N676D + FLT3 Y842C (3)

FLT3 mutation + DNMT3A mutation (3)

FLT3 mutation + NRAS mutation (3)

FLT3 wild-type (3)

FLT3-ITD mutation + FLT3 D835 (3)

FLT3-ITD mutation + MLL rearrangement (3)

FLT3-ITD mutation + NPM1 mutation (3)

FLT3‐ITD + NPM1 mutation (3)

FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation (3)

IDH wild-type (3)

FLT3 mutation + MLL mutation (2)

FLT3-ITD mutation + FLT3 D835Y (2)

FLT3-ITD mutation + FLT3 F691L (2)

FLT3-ITD mutation + IDH1 mutation (2)

FLT3-ITD mutation + IDH2 mutation (2)

FLT3-ITD mutation + WT1 mutation (2)

IDH1 wild-type + BRAF mutation (2)

IDH1 wild-type + NF1 mutation (2)

CEBPZ rearrangement + FLT3-TKD mutation (1)

FLT3 E588_Y589INSKYFYVDFRE (1)

FLT3 F691L + FLT3 D835F (1)

FLT3 F691L + FLT3 D835H (1)

FLT3 F691L + FLT3 D835V (1)

FLT3 F691L + FLT3 D835Y (1)

FLT3 F691L + FLT3 D839G (1)

FLT3 F691L + FLT3 Y842C (1)

FLT3 NPOS + FLT3 D835N (1)

FLT3 V592A + FLT3 D835N (1)

FLT3 V592_D593INSDFREY (1)

FLT3 Y591_V592INSVDFREYE (1)

FLT3 mutation + NRAS mutation + PTPN11 mutation (1)

FLT3 mutation + PTPN11 mutation (1)

FLT3 positive (1)

FLT3-ITD F692L + NPM1 mutation (1)

FLT3-ITD mutation + ASXL1 mutation (1)

FLT3-ITD mutation + ASXL1 mutation + NRAS mutation (1)

FLT3-ITD mutation + DNMT3A mutation + ASXL1 mutation (1)

FLT3-ITD mutation + DNMT3A mutation + NRAS mutation (1)

FLT3-ITD mutation + FLT3 D835Y + FLT3 F691L (1)

FLT3-ITD mutation + NRAS mutation + GATA2 mutation (1)

FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

FLT3‐ITD + DNMT3A mutation (1)

FLT3‐ITD + WT1 mutation (1)

MLL rearrangement + FLT3 mutation (1)

NPM1 mutation + FLT3-ITD mutation + TET2 mutation + CUX1 mutation (1)

NPM1 mutation + FLT3-TKD mutation (1)

NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation (1)

DNMT3A mutation + IDH mutation (1)

EGFR L858R + IDH1 R132C (1)

EGFR mutation + IDH1 mutation (1)

EGFR mutation+ IDH1 R132H (1)

IDH1 R132C + EGFR L861Q (1)

IDH1 R132C + IDH1 S280F (1)

IDH1 R132C + PIK3CA E545K + IDH2 R172K (1)

IDH1 R132H + PTEN C78T (1)

IDH1 mutation + TP53 mutation (1)

IDH1 rs1437410 (1)

FLT3 F691L + FLT3 Y842H (0)

FLT3-ITD F692L (0)

IDH mutation + BRAF V600E (0)

IDH mutation + Chr del(1p) + Chr del(19q) (0)

IDH mutation + Chr del(1p) + Chr del(19q) + BRAF V600E (0)

IDH mutation + Chr del(1p) + Chr del(19q) + NTRK fusion (0)

IDH mutation + NTRK fusion (0)

›

2ms

HOVON150AML: A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (clinicaltrials.gov)

P3, N=968, Active, not recruiting, Stichting Hemato-Oncologie voor Volwassenen Nederland | Recruiting --> Active, not recruiting | Trial completion date: May 2034 --> Sep 2034 | Trial primary completion date: Oct 2024 --> Apr 2027

2 months ago

Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy

|

FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)

|

IDH1 mutation • IDH2 mutation • FLT3 mutation • IDH1 R132 • UGT1A1*1*1 • FLT3 mutation + IDH1 mutation • IDH2 R140 • IDH2 R172 • UGT1A1 mutation

|

Tibsovo (ivosidenib) • Idhifa (enasidenib)

over1year

ACTIVITY, TOLERABILITY, AND RESISTANCE PROFILE OF THE MENIN INHIBITOR ZIFTOMENIB IN ADULTS WITH RELAPSED/REFRACTORY NPM1-MUTATED AML (EHA 2023)

Ziftomenib continues to demonstrate significant clinical activity in heavily pretreated and co-mutated R/R NPM1mAML pts where 35% of pts achieved CR. The safety profile remains consistent, and episodes of DS are clinicallymanageable. Data reveal that remissions are durable, with MRD clearance of NPM1 and key co-mutations.Resistance mutations develop infrequently, and ziftomenib remains effective against a common menin gatekeepermutation.

over 1 year ago

Clinical • Late-breaking abstract

|

FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • MEN1 (Menin 1)

|

FLT3 mutation • NPM1 mutation • KMT2A rearrangement • FLT3 mutation + IDH1 mutation

|

ziftomenib (KO-539)

over2years

Pharmacologic Strategies for Post-Transplant Maintenance in Acute Myeloid Leukemia: It Is Time to Consider! (PubMed, Cancers (Basel))

However, it's time to consider prophylactic pharmacologic interventions post allo-HCT that aim at maintaining leukemic clones under control by both direct cytotoxic activity and by enhancing the GVL effect. In this current review, available data on drugs targeting epigenetic pathways like azacitidine, or actionable mutations like FLT3 and IDH1/2 inhibitors used as maintenance post allo-HCT, will be discussed.

over 2 years ago

Review • Journal

|

FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)

|

FLT3 mutation • FLT3 mutation + IDH1 mutation

|

azacitidine